Physician profile
Lucy Saenz
NPI 1548367436
$5,446.90
in general payments reported to CMS, 2019-2025
12 companies · $1,317 in 2025
The $1,317 reported for 2025 was more than what 94% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $199 · 2021: $374 · 2022: $504 · 2023: $972 · 2024: $1,462 · 2025: $1,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,660 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,660.49 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,891.80 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $996.28 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $681.31 | 2024-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $656.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $313.00 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $302.44 | 2019-2023 | |
| Exact Sciences Corporation | $135.03 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $129.82 | 2023 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $120.25 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.61 | 2024 | Jardiance |
| Astellas Pharma US INC | $90.00 | 2024 | |
| Pfizer INC. | $13.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Saenz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.